What is claimed is:

1. Apraglutide, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of Graft versus Host Disease (GvHD) in a subject.

2. Use of apraglutide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing GvHD in a subject.

3. The use or apraglutide for use of any one of claims 1 or 2, wherein the GvHD is acute GvHD.

4. The use or apraglutide for use of any one of claims 1-3, wherein the GvHD is acute gastrointestinal GvHD.

5. The use or apraglutide for use of any one of claims 1 or 2, wherein the GvHD is chronic GvHD.

6. The use or apraglutide for use of any one of claims 1-5, wherein the GvHD is steroid-refractory.

7. The use or apraglutide for use of any one of claims 1-5, wherein the GvHD is steroid-naïve.

8. The use or apraglutide for use of any one of claims 1-7, wherein the GvHD is grade II-IV GvHD according to the MAGIC scale.

9. The use or apraglutide for use of any one of claims 1-8, wherein the apraglutide is to be administered to the subject:

(a) prior to the subject being administered a transplant; or

(b) prior the subject being administered radiation therapy, chemotherapy, or radiomimetic therapy in connection with a transplant.

10. The use or apraglutide for use of any one of claims 1-8, wherein the subject has been previously administered a transplant, preferably wherein the apraglutide, or pharmaceutically acceptable salt thereof, is to be administered to the subject after the subject has been administered a transplant.

11. The use or apraglutide for use of any one of claims 1-8, wherein the subject has been previously administered radiation therapy, chemotherapy, radiomimetic therapy or any combination thereof in connection with a transplant, preferably wherein the apraglutide, or pharmaceutically acceptable salt thereof, is to be administered to the subject after the subject has been administered radiation therapy, chemotherapy radiomimetic therapy or any combination thereof.

12. The use or apraglutide for use of any one of claims 1-8, wherein the apraglutide, or pharmaceutically acceptable salt thereof, is to be administered to the subject after the subject has been administered radiation therapy, chemotherapy radiomimetic therapy or any combination thereof and prior to the subject being administered a transplant.

13. The use or apraglutide for use of any one of claims 1-8, wherein the apraglutide, or pharmaceutically acceptable salt thereof, is to be administered to the subject:

(a) concurrently with a transplant; or

(b) concurrently with a radiation therapy, a chemotherapy, a radiomimetic therapy, or any combination thereof in connection with a transplant.

14. The use or apraglutide for use of any one of claims 1-13, wherein the administration of apraglutide, or pharmaceutically acceptable salt thereof, prevents and/or attenuates a reduction in colon length in a subject following:

(a) a transplant; or

(b) a conditioning therapy and a transplant.

15. The use or apraglutide for use of any one of claims 9-14, wherein the transplant comprises hematopoietic stem cells derived from bone marrow, peripheral blood, umbilical cord blood or any combination thereof, preferably wherein the transplant comprises T-cells, preferably
wherein the T-cells are chimeric antigen receptor (CAR) T-cells.

16. The use or apraglutide for use of any one of claims 9-15, wherein the radiation therapy comprises total body irradiation.

17. The use or apraglutide for use of any one of claims 1-16, wherein the pharmaceutically acceptable salt of apraglutide is the sodium salt of apraglutide.

18. The use or apraglutide for use of any one of claims 1-17, wherein the apraglutide, or pharmaceutically acceptable salt thereof, is to be administered by subcutaneous injection.

19. The use or apraglutide for use of any one of claims 1-18, wherein the apraglutide, or pharmaceutically acceptable salt thereof, is to be administered in an amount of between about 1 mg to about 10 mg.

20. The use or apraglutide for use of any one of claims 1-19, wherein the apraglutide is to be administered in an amount of about 2.5 mg.

21. The use or apraglutide for use of any one of claims 1-19, wherein the apraglutide is to be administered in an amount of about 5 mg.

22. The use or apraglutide for use of any one of claims 1-19, wherein the apraglutide is to be administered in an amount of about 10 mg.

23. The use or apraglutide for use of any one of claims 1-19, wherein
(a) the subject has a body weight of less than about 50 kg and the apraglutide is to be administered in an amount of about 2.5 mg;

(b) the subject has a body weight of about 50 kg to about 60 kg and the apraglutide is to be administered in an amount of about 2.5 mg or about 5 mg;

(c) the subject has a body weight of about 60 kg to about 80 kg and the apraglutide is to be administered in an amount of about 4 mg or about 7.5 mg; or

(d) the subject has a body weight of greater than about 80 kg and the apraglutide is to be administered in an amount of about 5 mg or about 10 mg.

24. The use or apraglutide for use of any one of claims 9-23, wherein the transplant is:

(a) an allogeneic transplant; or

(b) autologous transplant.

25. The use or apraglutide for use of any one of claims 1-24, wherein the subject has been previously administered at least one anti-GvHD therapy, preferably wherein the at least one anti-GvHD therapy comprises steroid therapy.